组织激肽释放酶8在神经系统疾病中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.04.0660

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (4): 660-664.doi: 10.16352/j.issn.1001-6325.2023.04.0660

组织激肽释放酶8在神经系统疾病中作用的研究进展

刘诗雨, 刘宇健^*

上海体育学院运动科学学院教育部运动与健康科学重点实验室上海市运动与代谢健康前沿科学研究基地,上海 200438

收稿日期:2021-10-14 修回日期:2022-06-02 出版日期:2023-04-05 发布日期:2023-04-03
通讯作者: ^*liuyujian@sus.edu.cn

Research progress on the role of kallikrein 8 in neurological diseases

LIU Shiyu, LIU Yujian^*

School of Kinesiology, the Key Laboratory of Exercise and Health Sciences of Ministry of Education, Shanghai Frontiers Science Research Base of Exercise and Metabolic Health,Shanghai University of Sport, Shanghai 200438, China

Received:2021-10-14 Revised:2022-06-02 Online:2023-04-05 Published:2023-04-03
Contact: ^*liuyujian@sus.edu.cn

摘要/Abstract

摘要： 组织激肽释放酶8(KLK8)与中枢神经系统的联系极为紧密,通过改变突触间的黏附关系和细胞外基质分子从而改变突触形态,调节突触可塑性,最终参与多种神经系统疾病的病理过程。本文针对KLK8的生理特性,对其在神经系统疾病如情绪障碍、阿尔茨海默病、癫痫、多发性硬化中的作用与发病机制进行综述。期待能够为神经系统疾病诊断和预后提供理论依据,为此类疾病的研究提供方向。

关键词: 激肽释放酶8, 突触可塑性, 情绪障碍, 阿尔茨海默病

Abstract: Kallikrein 8(KLK8) is closely related to the central nervous system and is involved in the pathological processes of many neurological diseases by altering inter-synaptic adhesion relationships and extracellular matrix molecules thereby modifying synaptic morphology and regulating synaptic plasticity. In this paper, we review the role and pathogenesis of KLK8 in neurological disorders such as dysthymic disorders, Alzheimer's disease, epilepsy, and multiple sclerosis with respect to its physiological properties. It is expected to provide a theoretical basis for the diagnosis and prognosis of neurological diseases and provide directions for the research of such diseases.

Key words: kallikrein 8, synaptic plasticity, dysthymic disorders, Alzheimer's disease

中图分类号:

刘诗雨, 刘宇健. 组织激肽释放酶8在神经系统疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 660-664.

LIU Shiyu, LIU Yujian. Research progress on the role of kallikrein 8 in neurological diseases[J]. Basic & Clinical Medicine, 2023, 43(4): 660-664.

参考文献

[1]Pampalakis G, Zingkou E, Panagiotidis C, et al. Kallikreins emerge as new regulators of viral infections[J]. Cell Mol Life Sci, 2021, 78: 6735-6744.
[2]Di Paolo, Diamandis EP, Prassas I. The role of kalli-kreins in inflammatory skin disorders and their potential as therapeutic targets[J]. Crit Rev Clin Lab Sci, 2021, 58: 1-16.
[3]Mella C, Figueroa CD, Otth C, et al. Involvement of Kallikrein-related peptidases in nervous system disorders[J]. Front Cell Neurosci, 2020, 14: 166.doi:10.3389/Fncel.2020.00166.
[4]Bukowski L, Chernomorchenko AMF, Starnawska A, et al. Neuropsin in mental health[J]. J Physiol Sci, 2020, 70: 26.
[5]Konar A, Thakur MK. Neuropsin expression correlates with dendritic marker MAP2c level in different brain regions of aging mice[J]. Mol Neurobiol, 2015, 51: 1130-1138.
[6]Konar A, Kumar A, Maloney B, et al. A serine protease KLK8 emerges as a regulator of regulators in memory: Microtubule protein dependent neuronal morphology and PKA-CREB signaling[J]. Sci Rep, 2018, 8: 9928.doi:10.1038/s41598-018-27640-6.
[7]He X, Wang Y, Zhou G, et al. A critical role for gammaCaMKII in decoding NMDA signaling to regulate AMPA receptors in putative inhibitory interneurons[J]. Neurosci Bull, 2022. doi:10.1007/s12264-022-00840-x.
[8]Attwood BK, Bourgognon JM, Patel S, et al. Neuropsin cleaves EphB2 in the amygdala to control anxiety[J]. Nature, 2011, 473: 372-375.
[9]Nakazawa H, Suzuki Y, Ishikawa Y, et al. Impaired social discrimination behavior despite normal social approach by kallikrein-related peptidase 8 knockout mouse[J]. Neurobiol Learn Mem, 2019, 162: 47-58.
[10]Ishikawa Y, Tamura H, Shiosaka S. Diversity of neuropsin (KLK8)-dependent synaptic associativity in the hippocampal pyramidal neuron[J]. J Physiol, 2011, 589: 3559-3573.
[11]Yang J, Kang C, Wu C, et al. Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia[J]. Schizophr Res, 2021, 231: 67-69.
[12]Chang S, Bok P, Sun CP, et al. Neuropsin inactivation has protective effects against depressive-like behaviours and memory impairment induced by chronic stress[J]. PLoS Genet, 2016, 12: e1006356, doi:10.1371/journal.pgen.1006356.
[13]Bobinska K, Mossakowska-Wojcik J, Szemraj J, et al. Human neuropsin gene in depression[J]. Psychiatr Danub, 2017, 29: 195-200.
[14]Schramm S, Jokisch M, Jockel KH, et al. Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study[J]. Alzheimers Res Ther, 2021, 13: 202.doi:10.1186/s13195-021-00945-x.
[15]Herring A, Kurapati NK, Krebs S, et al. Genetic knockdown of Klk8 has sex-specific multi-targeted therapeutic effects on Alzheimer's pathology in mice[J]. Neuropathol Appl Neurobiol, 2021, 47: 611-624.
[16]Munster Y, Keyvani K, Herring A. Inhibition of excessive kallikrein-8 improves neuroplasticity in Alzheimer's disease mouse model [J]. Exp Neurol, 2020, 324: 113-115.
[17]Keyvani K, Munster Y, Kurapati NK, et al. Higher levels of kallikrein-8 in female brain may increase the risk for Alzheimer's disease[J]. Brain Pathol, 2018, 28: 947-964.
[18]Drucker KL, Gianinni C, Decker PA, et al. Prognostic significance of multiple kallikreins in high-grade astrocytoma[J]. BMC Cancer, 2015, 15: 565.doi:10.1186/s12885-015-1566-5.
[19]Srinivasan S, Kryza T, Batra J, et al. Remodelling of the tumour microenvironment by the kallikrein-related peptidases[J]. Nat Rev Cancer, 2022, 22: 223-238.
[20]Panos M, Christophi GP, Rodriguez M, et al. Differen-tial expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response[J]. Biol Chem, 2014, 395: 1063-1073.
[21]Missault S, Peeters L, Amhaoul H, et al. Decreased levels of active uPA and KLK8 assessed by[(111)In]MICA-401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy[J]. Epilepsia, 2017, 58: 1615-1625.
[22]Kawata M, Morikawa S, Shiosaka S, et al. Ablation of neuropsin-neuregulin 1 signaling imbalances ErbB4 inhibitory networks and disrupts hippocampal gamma oscillation[J]. Transl Psychiatry, 2017, 7: e1052, doi:10.1038/tp.2017.20.
[23]Ray B, Sokol DK, Maloney B, et al. Finding novel distinctions between the sAPP-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue[J]. Sci Rep, 2016, 6: 26-52.
[24]Diab A, Qi J, Shahin I, et al. NCK1 regulates amygdala activity to control context-dependent stress responses and anxiety in male mice[J]. Neuroscience, 2020, 448: 107-125.

组织激肽释放酶8在神经系统疾病中作用的研究进展

Research progress on the role of kallikrein 8 in neurological diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王远卓, 郑清月, 张翰林, 仇文颖, 王涛, 马超. 小胶质细胞在阿尔茨海默病神经炎性反应中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1310-1313.
[2]	徐娟, 李晔. 铁死亡在阿尔茨海默病中作用的研究进展[J]. 基础医学与临床, 2022, 42(7): 1129-1133.
[3]	路亚岚, 周澧, 韩云林, 王克维, 秦川. 冈田酸诱导人神经母细胞瘤细胞系SH-SY5Y损伤[J]. 基础医学与临床, 2022, 42(6): 927-932.
[4]	沈杰, 严洁, 钟明, 庞睿娟, 罗永杰. LncRNA SNHG14调控miR-142-5p对寡聚态Aβ诱导的鼠源神经细胞系PC12损伤的影响[J]. 基础医学与临床, 2022, 42(6): 913-919.
[5]	孙健茹, 仇文颖, 钱晓菁, 马超. Fc-gamma Ⅰ型受体在阿尔茨海默病患者和模型小鼠脑皮质的表达[J]. 基础医学与临床, 2022, 42(5): 740-744.
[6]	孙静瑶, 佟伟民, 牛亚梅. mRNA转录后调控异常在阿尔茨海默病发病机制中的研究进展[J]. 基础医学与临床, 2021, 41(5): 749-752.
[7]	孙添怡, 刘帆, 仇文颖, 马超. piRNAs在阿尔茨海默病患者脑中的差异表达[J]. 基础医学与临床, 2021, 41(4): 533-538.
[8]	王紫涵, 罗金定, 田英入, 奉水东, 凌宏艳. 小胶质细胞引起和促进阿尔茨海默病的研究进展[J]. 基础医学与临床, 2021, 41(2): 277-281.
[9]	刁华琼, 李小黎, 林亮吟, 刘海鹏, 陈弘婧, 丁海月, 魏丹. 外泌体microRNAs与阿尔茨海默病关系的研究进展[J]. 基础医学与临床, 2020, 40(11): 1542-1545.
[10]	曾利敏, 鲁召辉, 周丽平, 朱超霞. 甲基莲心碱通过调控miR-29a-3p/AQP4表达抑制Aβ1-42致PC12细胞的损伤[J]. 基础医学与临床, 2020, 40(1): 83-91.
[11]	杜亚云刘晓丽朱席琳伍晓盼刘英. 胱硫醚β合成酶通过ATG5巯基化促进自噬缓解阿尔茨海默病[J]. 基础医学与临床, 2019, 39(7): 983-988.
[12]	刘建玉夏春娥赵雪梅梁平. CB-Aβ抗体偶联物抑制痴呆小鼠脑内Aβ纤维斑块形成[J]. 基础医学与临床, 2013, 33(7): 834-839.
[13]	谷心灵李良. 氧化应激上调人神经母细胞瘤细胞内β-裂解酶的表达 [J]. 基础医学与临床, 2012, 32(4): 359-362.
[14]	李彦玮常德赵雪梅梁平. 抗Aβ鼠源单克隆抗体的人源化改造及其表达鉴定[J]. 基础医学与临床, 2010, 30(8): 862-867.
[15]	雷甜甜赵雪梅梁平. 不同Aβ多肽与佐剂组合免疫小鼠对Th1/Th2平衡的调节作用[J]. 基础医学与临床, 2009, 29(6): 618-621.